The lower product sales outlook versus 2025 reflects continued growth in core commercial brands, offset by the planned wind-down of third-party sales.

The vaccine maker said it will maintain disciplined cash management, with operating cash burn expected to decline further in 2026 while continuing to fund strategic R&D.

For 2025, Valneva reported preliminary unaudited revenue of €174.7M, up from €169.6M in 2024. Product sales totaled €157.9M, down from €163.3M a year earlier, mainly due to a 42.3% drop in third-party sales to €19.2M.

Cash and cash equivalents were €109.7M as of Dec. 31, 2025, compared with €168.3M at the end of 2024.

CFO Peter Bühler, commented, “2025 challenged our resilience while reaffirming the strength of our team’s disciplined execution. We remained committed to growing our commercial brands and made strong progress across our key R&D programs, despite headwinds around IXCHIQ and the broader geopolitical pressures. As we enter 2026, we look forward to the potentially transformative Phase 3 data readout for our Lyme disease vaccine candidate, while remaining focused on prudent capital allocation, to support shaping and growing our business in line with our strategic vision.”

Separately, Valneva (VALN) renewed Thomas Lingelbach’s mandate as CEO for a further three-year term and confirmed his continued role as a board member.

The post Valneva sees lower 2026 sales as third-party revenue winds down appeared first on Up2info.com.

The revised recommendations from the United Kingdom’s Commission on Human Medicines suggest that Ixchiq continues to offer a favorable benefit–risk profile in people aged 18–59 years who are without contraindicated conditions but at risk of contracting chikungunya.

However, the CHM has recommended restricting its use in people older than 60 those with specific health conditions such as immunodeficiencies and added timing restrictions for its administration.

In June, pending a safety review, the CHM temporarily suspended the use of the live-attenuated vaccine in people aged 65 years and older after multiple countries reported very rare but fatal reactions.

In 2023, the U.S. FDA approved Ixchiq as the world’s first chikungunya shot, only to suspend its authorization last August due to safety concerns.

The post Valneva chikungunya shot no longer recommended for older adults in U.K. appeared first on Up2info.com.

The companies identified the decision as a strategic move aimed at improving vaccine access in regions endemic to chikungunya, which falls within an EU-backed funding agreement Valneva (VALN) has signed with CEPI, a global vaccine alliance.

“Valneva’s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accelerating access for regions most affected by the disease,” Valneva (VALN) and Serum Institute said.

A mosquito-borne viral disease characterized by severe joint pain persisting for weeks to years, chikungunya is found across more than 110 countries in Asia, Africa, Europe, and the Americas.

In November 2023, the U.S. FDA approved the French biotech’s (VALN) single-dose shot Ixchiq as the world’s first chikungunya vaccine, only to suspend the authorization in August due to safety concerns.

The post Valneva ends chikungunya vaccine deal with India’s Serum Institute appeared first on Up2info.com.

The New York State Department of Health confirmed the finding on Tuesday based on Laboratory testing conducted at the department’s Wadsworth Center, according to Reuters. Citing existing information, the agency categorized the case as “locally acquired” but noted that the exact origin of the infection remained unclear.

However, according to the county health department, the individual started to develop chikungunya symptoms in August after travelling outside the region, but not outside the country, the Associated Press reported.

Chikungunya, a viral disease characterized by fever and joint pain, among other signs and symptoms, was a rarely identified illness among U.S. travelers until 2006. However, as of Sept. 30, the CDC has confirmed 88 travel-associated chikungunya cases in the U.S. this year. Local transmissions, where people acquire the disease through infected mosquitoes, were last reported in the U.S. in 2019.

Makers of FDA-approved chikungunya vaccines: Valneva (NASDAQ:VALN), Bavarian Nordic (OTCPK:BVNRY) (BAVN) (OTCPK:BVNKF).

The post New York reports first locally acquired chikungunya case in U.S. since 2019 appeared first on Up2info.com.

The post Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing appeared first on Up2info.com.

Here are some of Monday’s biggest stock movers:

Biggest stock gainers

• Vital Energy (NYSE:VTLE) +17% – Shares jumped after reports surfaced that Crescent Energy (CRGY) is in advanced talks to acquire the smaller Permian Basin producer, with a deal potentially to be announced as soon as this week. No financial terms have been disclosed. Crescent has a market value of about $2.5B, while Vital has a market value of approximately $600M; however, Vital also carries around $2.3B in long-term debt. For FY2024, Vital reported production of 133,845 boe/day, up 38% from 96,591 boe/day in FY2023.
• Nio (NYSE:NIO) +6% – Shares extended gains after a 14% surge on Friday, fueled by the unveiling of the company’s new ES8 SUV on Aug. 21. Priced at 308,800 yuan ($43,000) under a battery subscription plan, the ES8 is among Nio’s most affordable models. For comparison, its premium SUVs are typically priced between 338,000 and 768,000 yuan. The subscription plan reduces upfront costs and offers customers the flexibility to swap or upgrade batteries for a monthly fee. Deliveries are expected to begin in late September.

Biggest stock losers

The post Biggest stock movers Monday: NIO, VALN, and more appeared first on Up2info.com.

The FDA initially cleared the shot in November 2023 under its accelerated approval pathway to prevent chikungunya, a mosquito-borne viral disease, in individuals aged 18 years and older who are at an increased risk of contracting the virus.

The decision to suspend its marketing application was “based on serious safety concerns related to the vaccine, which appears to be causing chikungunya-like illness in vaccine recipients,” the regulator said.

The FDA has recorded one mortality directly linked to Ixchiq and more than 20 serious adverse events similar to chikungunya-like illness in those who received the live-attenuated vaccine.

Overall, there have been 21 hospitalizations and three deaths, the agency noted, adding that Ixchiq’s clinical benefit has not yet been proven in confirmatory trials and the vaccine’s benefits do not outweigh its risks according to a benefit-risk analysis conducted by the FDA’s biologics division.

“For these reasons, CBER believes this vaccine is not safe and that continued administration to the public would pose a danger to health,” the regulator added.

The decision comes in the same month that the FDA and CDC removed a recommended pause in the use of Ixchiq in those aged 60 years and older, after requiring labeling changes to the shot following an investigation into serious adverse events linked to the vaccine.

Other operators in the U.S. chikungunya vaccine market include Danish biotech Bavarian Nordic (BAVN) (OTCPK:BVNRY) (OTCPK:BVNKF).

The post Valneva suspended from marketing chikungunya shot in U.S. over safety concerns appeared first on Up2info.com.

The post Valneva reports 1H results; reaffirms FY outlook appeared first on Up2info.com.

Valneva SE (NASDAQ:VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, for individuals aged 60 and older and has updated the prescribing information for the vaccine.

This decision follows a

The post FDA lifts pause on Valneva’s chikungunya vaccine in elderly appeared first on Up2info.com.

The Centers for Disease Control and Prevention (CDC) in the United States weighs releasing a travel advisory for China due to an increase in chikungunya cases, according to a report by Bloomberg News citing a spokesperson.

The spokesperson stated, “The CDC is aware of the chikungunya outbreak reported in Guangdong Province, China, and is currently evaluating the scale and impact of the situation.”

Since the first case was reported in early July, China has documented nearly 5,000 instances of this mosquito-transmitted disease.

The post CDC mulls travel notice for China amid rise in chikungunya cases appeared first on Up2info.com.